# Pharmecons Easy Access Ltd > A pharmacoeconomics company ## Posts - [3rd Panhellenic Conference of the Hellenic Society of Digital Medicine](https://pharmecons.com/3rd-panhellenic-conference-of-the-hellenic-society-of-digital-medicine/): The digital transformation of healthcare providers is critical for improving patient outcomes, operational efficiency, and system-wide sustainability. This session aims to explore the unique challenges and needs of healthcare providers in adopting digital solutions while highlighting their transformation journey. - [Athens Digital Health Week 2025](https://pharmecons.com/athens-digital-health-week-2025-29-01-25/): The digital transformation of healthcare providers is critical for improving patient outcomes, operational efficiency, and system-wide sustainability. This session aims to explore the unique challenges and needs of healthcare providers in adopting digital solutions while highlighting their transformation journey. - [Semantic Interoperability for an AI-based Applications Platform for Smart Hospitals Using HL7 FHIR / Journal of Systems & Software](https://pharmecons.com/semantic-interoperability-for-an-ai-based-applications-platform-for-smart-hospitals-using-hl7-fhir-journal-of-systems-software/): The digitization of the healthcare domain has the potential to drastically improve healthcare services, reduce the time to diagnosis, and lower costs. However, digital applications for the healthcare domain need to be interoperable to maximize their potential. Additionally, with the rapid expansion of Artificial Intelligence (AI) and, specifically, Machine Learning (ML), large amounts of diverse types of data are being utilized. Thus, to achieve interoperability in such applications, the adoption of common semantic data models becomes imperative. - [Stronger Together – Pharmecons Easy Access Ltd & Exzellia Pharma Ltd.](https://pharmecons.com/stronger-together-pharmecons-easy-access-ltd-exzellia-pharma-ltd/): We are excited to announce that Pharmecons Easy Access Ltd. has entered into a collaboration with Exzellia Pharma Ltd. and Dr. Stalo Charalambous. Through this partnership, Pharmecons will enhance its footprint and activities in Cyprus and Malta, leveraging Dr. Charalambous' extensive knowledge and expertise in the healthcare landscapes of these regions, along with her extensive experience in the multinational pharmaceutical industry. - [8th Health Technology Assessment](https://pharmecons.com/8th-health-technology-assessment/): Η Μάγδα Χατζίκου, Partner PharmEcons Easy Access Ltd, ΣΕΠ Ελληνικό Ανοικτό Πανεπιστήμιο στο πλαίσιο της ομιλίας της στο 8ο Ετήσιο Συνέδριο ΗΤΑ με παράδειγμα την εφαρμογή HosmartAI (ένα επιδοτούμενο πρόγραμμα του Ορίζοντα 2020), αναφέρθηκε στην ανάγκη να τεθεί σύντομα το πλαίσιο αξιολόγησης των ιατροτεχνολογικών εφαρμογών και άλλων τεχνολογιών τεχνητής νοημοσύνης και στην Ελλάδα. - [Proposal on the European Health Data Space](https://pharmecons.com/proposal-on-the-european-health-data-space/): The European Health Data Space (‘EHDS’) is the first proposal of such domain-specific common European data spaces. It will address health-specific challenges to electronic health data access and sharing, is one of the priorities of the European Commission in the area of health 2 and will be an integral part of building a European Health Union. - [Treatment pathways and associated costs of metastatic colorectal cancer in Greece](https://pharmecons.com/treatment-pathways-and-associated-costs-of-metastatic-colorectal-cancer-in-greece/): Colorectal cancer (CRC) is the second leading cause of cancer in Europe, with 1.931.590 people newly diagnosed in 2020. The purpose of this study is the investigation of treatment options and healthcare resource meta- static CRC (mCRC) in Greece. - [Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland, Spain](https://pharmecons.com/pf-for-breast-cancer-treatments-dce-in-france-ireland-poland-spain/): The authors wanted to explore what breast cancer patients want the most from their cancer treatments. For this purpose, their preferences were collected in four European countries via a discrete choice experiment. The study showed that patients prefer treatments that improve their ability to function well in their daily lives and reduce their levels of pain. Patients’ preferences for treatment outcomes might differ from those of the treating clinicians or regulators. Hence, these aspects can be discussed with their clinicians to make a joint decision on the choice of treatments. - [Regulation on health technology assessment](https://pharmecons.com/regulation-on-health-technology-assessment/): The Regulation (EU) 2021/2282 on health technology assessment (HTAR) contributes to improving the availability for EU patients of innovative technologies in the area of health, such as medicines and certain medical devices. It ensures an efficient use of resources and strengthens the quality of HTA across the Union. It provides a transparent and inclusive framework by establishing a Coordination Group of HTA national or regional authorities, a stakeholder network and by laying down rules on the involvement in joint clinical assessments and joint scientific con-sultations of patients, clinical experts and other relevant experts. The HTAR will also reduce duplication of efforts for national HTA authorities and industry, facilitate business predictability and ensure the long-term sustainability of EU HTA cooperation. - [MCR Disease Management of Metastatic Melanoma](https://pharmecons.com/mcr-disease-management-of-metastatic-melanoma/): Disease Management and Resource Use for the Management of Melanoma stage IIIc or IV Positive for BRAF V600 Mutations in Greece Objective: Melanoma is one of the most aggressive cancers and is responsible for the majority of skin cancer deaths, with the presence of metastases prognostic for poor survival. At a time when most cancer incidences are falling, the annual incidence of melanoma has risen as rapidly as 4-6% in many European countries, with a substantial economic burden in advanced stages. The objective of this study is the investigation of treatment pathways and healthcare resource use related to advanced BRAF-mutated melanoma in Greece. - [HosmartAI](https://pharmecons.com/hosmartai/): HosmartAI EU Project, an amazing and ambitious journey for Pharmecons Easy Access who will perform the economic evaluation of the AI technologies has just started! On the last 9-10 February, took place the kick-off meeting of the new project HosmartAI – “Hospital Smart development based on AI”. The project is funded by €10 million under European Union’s Horizon 2020 research and innovation programme (Grant Agreement No 101016834). - [Hellenic Atherosclerosis Society](https://pharmecons.com/hellenic-atherosclerosis-society/): Η Ελληνική Εταιρία Αθηροσκλήρωσης σε συνεργασία με τη συμβουλευτική εταιρία Pharmecons Easy Access που εξειδικεύεται σε θέματα τιμολόγησης και αποζημίωσης τεχνολογιών υγείας στην Ευρώπη και στην Ελλάδα διοργανώνει πρόγραμμα/σεμινάριο (satellite) στο πλαίσιο του ετήσιου συνεδρίου της Ελληνικής Εταιρίας Αθηροσκλήρωσης, την Πέμπτη 29 Νοεμβρίου 2018 και ώρα 11:00-15:00 στο Ξενοδοχείο Divani Caravel, αίθουσα Μυκήνες. - [HTA Seminar PEF 2018](https://pharmecons.com/hta-seminar-pef-2018/): Σεμινάριο Οικονομικών Φαρμάκων Αξιολόγηση και Αποζημίωση φαρμάκων: Νέα δεδομένα ## Pages - [Research Programs](https://pharmecons.com/research-programs/): Through close collaboration with academic institutions, healthcare providers, industry partners, patient organisations, and public authorities, we support the successful design, implementation, and long-term impact of collaborative research initiatives. - [News](https://pharmecons.com/news/): Home Read More Read More April 6, 2024 / NewsWe are excited to announce that Pharmecons Easy Access Ltd. - [Privacy Policy](https://pharmecons.com/privacy-policy/): We would like to assure you that for Pharmecons Easy Access (the “Company”), the protection of the personal data of its shareholders and investors and any other case where there is identification of natural persons and users of our website is of paramount importance. - [Communication](https://pharmecons.com/communication/): Pharmecons Easy Access ensures the publication of the generated evidence from the projects which undertakes. - [Careers](https://pharmecons.com/careers/): At Pharmecons, we are an ever expanding, dynamic team and we are always happy to receive enquiries from health economists, modellers, systematic reviewers and medical writers with at least two years’ experience. - [404](https://pharmecons.com/404-2/) - [Contact](https://pharmecons.com/contact/): 35 Agiou Georgiou & Irous St. - [Services](https://pharmecons.com/services/): Economic modelling is a focal point of the economic evaluation of a new health technology, since it supports the decision making by bringing together the evidence on costs, outcomes and epidemiological data. - [About](https://pharmecons.com/about/): Home Pharmecons is an international outcomes research agency specializing in market access issues, health economics and patient-reported outcomes (PRO). - [Home](https://pharmecons.com/): Through the use of our multi-disciplinary expertise from pharmaceutical and medical devices, regulatory, clinical and market access experience, we seek to provide individualized solutions to Pharma & Medical Device Industry to best support products’ added value. [comment]: # (Generated by Hostinger Tools Plugin)